Garen G. Bohlin - 14 May 2024 Form 4 Insider Report for COLLEGIUM PHARMACEUTICAL, INC (COLL)

Role
Director
Signature
/s/ Shirley R. Kuhlmann as Attorney-in-Fact for Garen G. Bohlin
Issuer symbol
COLL
Transactions as of
14 May 2024
Net transactions value
-$770,227
Form type
4
Filing time
16 May 2024, 19:20:35 UTC
Previous filing
12 Sep 2023
Next filing
30 May 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction COLL Common Stock Options Exercise $166,084 +28,985 +65% $5.73 73,760 14 May 2024 Direct
transaction COLL Common Stock Sale $936,311 -28,985 -39% $32.30 44,775 14 May 2024 Direct F1
transaction COLL Common Stock Award $0 +7,693 +17% $0.000000 52,468 16 May 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction COLL Stock Option (Right to Purchase) Options Exercise $0 -28,985 -100% $0.000000* 0 14 May 2024 Common Stock 28,985 $5.73 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.
F3 The option is fully vested and exercisable.